Congratulations to Band portfolio company Seal Rock Therapeutics for securing a $547,000 grant from the U.S. Army Medical Research Acquisition Activity (USAMRAA) to support preclinical evaluation of Seal Rock’s ASK1 inhibitor, SRT-055, as a potential development candidate for amyotrophic lateral sclerosis (ALS). https://lnkd.in/g77kV8q2